Search results

Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia.

Result type

Technology appraisal guidance

Published

28 September 2016

Evidence-based recommendations on lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory large B-cell lymphoma in adults after first-line chemoimmunotherapy when a stem cell transplant is suitable.

Result type

Technology appraisal guidance

Published

26 March 2025

Evidence-based recommendations on ponatinib (Iclusig) for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults.

Result type

Technology appraisal guidance

Published

28 June 2017

Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease.

Result type

Technology appraisal guidance

Published

25 November 2020

Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.

Result type

Technology appraisal guidance

Published

21 June 2023

Evidence-based recommendations on cabazitaxel (Jevtana) for people with prostate cancer that has come back after it was treated with docetaxel.

Result type

Technology appraisal guidance

Last updated

24 August 2016

Evidence-based recommendations on lenalidomide (Revlimid) for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality in adults.

Result type

Technology appraisal guidance

Last updated

26 June 2019